Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

1. Johnston, S.R.D.
2. Toi, M.
3. O'Shaughnessy, J.
4. Rastogi, P.
5. Campone, M.
6. Neven, P.
7. Huang, C.-S.
8. Huober, J.
9. Jaliffe, G.G.
10. Cicin, I.
11. Tolaney, S.M.
12. Goetz, M.P.
13. Rugo, H.S.
14. Senkus, E.
15. Testa, L.
16. Del Mastro, L.
17. Shimizu, C.
18. Wei, R.
19. Shahir, A.
20. Munoz, M.
21. San Antonio, B.
22. André, V.
23. Harbeck, N.
24. Martin, M.